Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
In the past few years, market trends for Refsum disease, a rare genetic trait in which the body builds up phytanic acid, have changed. There are many things that can change the market for Refsum disease, which is sometimes written as REFSUM. These include new scientific discoveries and help for patients.
One interesting trend is that more and more doctors, patients, and people in general are learning about Refsum disease. Patient groups and drug firms have worked together on awareness efforts that have taught many people about the disease's signs, how to diagnose it, and the different treatments that are available.
Over time, better ways to diagnose diseases have made it easier to find and name people who have Refsum disease. This has helped find more people, which makes it easier to treat and keep things under control. Testing tools that work better and are easier to use are a big part of what has moved the market forward.
There are some good changes in the way that Refsum disease is handled now. Scientists are trying to figure out the changes and processes in DNA that cause these diseases. This has led to the search for treatments that are specific to each person. More and more people are taking part in studies to find new treatments. This gives patients hope and makes the market grow.
Orphan drugs have been thought of as a possible cure for Refsum disease because it is so rare. The goal of this governmental support is to encourage drug companies to spend money on research and development for these uncommon conditions, which will make the market situation better.
The market trends show a change toward ways that focus on the patient, with a focus on making people with Refsum disease's quality of life better. Patient support groups have been very important in creating these trends by working with different parties, choosing what research should focus on, and pushing for easy access to new treatments.
The speed of research and development has been sped up by global agreements between drug businesses, study schools, and government bodies. The goal of these interactions is to share resources, information, and data in order to create a working setting where people can work together to fix problems caused by rare diseases like Refsum.
Making sure that treatments for Refsum disease are easy to get and don't cost too much is still very important. A commitment to making new treatments available to a wider range of patients is shown by the growing focus on fair access to drugs and efforts to deal with price problems.
Adding cutting edge technologies, like gene editing and personalized medicine, to the creation of treatments for Refsum disease has been a big change. The coming together of technology and healthcare is likely to improve treatment plans even more, leading to better results for patients.
The market trends for Refsum disease have been changed by changes in the rules that apply to rare illnesses. All over the world, regulatory bodies are changing to deal with the unique problems that rare diseases cause. They are speeding up the process for clearing drugs and making sure that research and development can happen in a good setting.
Refsum Disease Market Highlights:
Refsum Disease Market Overview
The Refsum Disease Market Size was valued at USD 0.74 Billion in 2023. The Global Refsum Disease industry is projected to grow from USD 0.69 Billion in 2024 to USD 2.48 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.03% during the forecast period (2024 - 2032). Refsum disease is a genetic disorder which is inherited as an autosomal recessive trait.
The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene that metabolizes phytanic acid. According to the U.S. National Library of Medicine, more than 90 % cases of refsum disease result from the mutations in PHYH gene, and the remaining cases are caused by mutations in a gene PEX7 gene.
Notably, increasing awareness among people is the key factor driving the refsum disease market. According to the National Organization of Rare Diseases, the age of onset of refsum disorder varies greatly. The disease can occur at any time from early childhood to nearly 50 years of age, but in most cases will have appeared by age 20. Males and females are equally affected in numbers.
Various other push factors such as increasing awareness among people, increasing government assistance, improving regulatory framework, and rising funding and reimbursement continuously contributing to the growth of the refsum disease market.
Despite these drivers, there are some issues associated with refsum disease market. Some of the challenges in research and development, and poor healthcare system in low and middle-income countries may hinder the growth of the market to some extent.
Intended Audience
- Pharmaceutical Companies
- Hospitals & Clinics
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Refsum Disease Market Segmentations
The refsum disease market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into adult refsum disease, and others. The adult refsum disease is further segmented into adult refsum disease 1, and adult refsum disease 2.
On the basis of the diagnosis, the market is classified into physical examination, molecular genetic testing, prenatal screening tests, preimplantation genetic diagnosis, enzyme analysis, anosmia testing, and others. The molecular genetic testing is further segmented into genotyping, sequencing of gene, amplification or hybridization method, methylation-specific techniques, and others. The prenatal screening tests are further segmented into ultrasound, blood tests, chorionic villus sampling (CVS), amniocentesis, and others.
On the basis of the treatment, the market is classified as medical care, and surgical care. The medical care is further segmented into diet, plasmapheresis, and medication. The sub-segments of medication include keratolytics, and others.
On the basis of the end-user, the market is segmented into hospital, clinics, diagnostic centers, research & academic institutes, and others.
Refsum Disease Market Regional Analysis
The Americas dominate the refsum disease market owing to the rising awareness among people and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the refsum disease market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in healthcare is likely to drive the market of the European region.
The Asia Pacific is the fastest growing refsum disease market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
Refsum Disease Market Key Players
Some of key the players in the refsum disease market are:
- Fresenius Kabi
- B. Braun Medical Inc.
- Medline Industries, Inc.
- Illumina, Inc.
- Igenomix
- Ceuta Healthcare Limited
- Cochlear Ltd.
- Cook
- Sonova
- William Demant Holding A/S
- Nurotron Biotechnology Co. Ltd.
- Agilent Technologies
- Bio-Rad Laboratories, Inc.
- Sequenom
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
